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ABSTRACT
 Curcumin was reported to reverse the decrease in histone deacetylase-2 (HDAC2) protein 
expression in inflammatory diseases of the lung, including chronic obstructive pulmonary disease 
(COPD), severe asthma, and asthma in smokers. This indicates that curcumin is a potent ligand for 
HDAC2. The construction and retrospective validation of a structure-based virtual screening (SBVS) 
protocol to identify potent ligands for HDAC2 are presented in this article. The validated protocol 
was subsequently employed to screen curcumin and other curcuminoids found in Curcuma longa, 
i.e.demethoxycurcumin and bis-demethoxycurcumin, and to examine their interactions to HDAC2 in 
the atomic level. The results show that curcumin, demethoxycurcumin and bis-demethoxycurcumin 
are potent HDAC2 ligands. The insights from their interactions to HDAC2 resulted from the molecular 
docking simulations presented in this article could be employed further in the design and discovery 
potent HDAC2 ligands. 
Key words: Curcuminoid, histone deacetylase-2 (HDAC2), structure-based 
virtual screening, molecular docking.
INTRODUCTION
 Histone deacetylase 2 (HDAC2) plays an 
important role in physiological insulin signaling, 
the pathophysiology of the failing heart1, memory 
formation2, the pathophysiology of airway disease3, 
and also in the regulation of cell cycle and apoptosis4. 
Targeting HDAC2 to discover novel ligands for HDAC2 
can therefore serve in the new therapeutic strategies 
against diabetes mellitus, myocardial injury, memory 
impairment, airway disease and cancer1–4. Inhibition 
of HDAC2 restored insulin signaling in both type 1 
and type 2 diabetes mellitus by increasing GLUT4 
translocation and augmenting basal and insulin-
induced glucose up-take in skeletal muscle, returned 
to normal level of ventricular function by inhibit 
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autophagy1, ameliorated reduced synapse number 
and learning impairment2, and repressed tumor cell 
growth and activated cellular apoptosis via p53 and 
Bax activation and Bcl2 suppression4. Meanwhile, 
HDAC2 activator such as curcumin restored 
corticosteroid sensitivity, suppressed inflammatory 
gene expression and treating corticosteroid-resistant 
inflammatory diseases of the lung, including COPD, 
severe asthma, and asthma in smokers3. Moreover 
the novel ligands can support as tools in the research 
to unravel the prominent role of HDAC2. A combined 
LBVS/SBVS approaches to design novel ligands for 
HDAC2 has been done and suggested 26 putative 
HDAC2 ligands5. Xiang et al.5 has suggested that 
aninteraction with zinc ion and strong hydrogen 
bonds should be formed by the putative ligands. 
 In patients with chronic obstructive pulmonary 
disease (COPD) caused by oxidative stress as a 
result of cigarette smoking, curcumin was reported 
to reverse the decrease in histone deacetylase-2 
(HDAC2) protein expression6. This indicates that 
curcumin is a potent ligand for HDAC23,6,7. Curcumin 
is an active compound found in turmeric (Curcuma 
longa), which co-exist with other curcuminoids 
demethoxy curcumin and bis-demethoxy curcumin8 
(Figure 1). These compounds have been reported 
having similar pharmacological activities, i.e. as free 
radical scavenger, antioxidant, anti-inflammatory, 
anticarcinogenic, and neuroprotective agents9. 
Therefore, study on curcuminoids as ligands for 
HDAC2 could provide insights in the design of 
novel ligands for HDAC2 as well as unraveling 
other applications of curcuminoids in the prevention 
or therapy of memory impairment and airway 
disease.
 Following the successful attempts of Xiang 
et al.5, the research presented in this article aimed 
to employ the systematic filtering on protein-ligand 
interaction fingerprints (PLIF)10,11 as suggested12,13 
in SBVS campaigns to identify HDAC2 ligands 
among their decoys14. The SBVS campaigns 
employing PLANTS1.2 docking software15,16 as 
the backbone of the protocol17. The retrospectively 
validated protocol by using database of HDAC2 
ligands and decoys provided by Mysinger et al.14 
was subsequently employed to examine virtually if 
curcuminoids18,19were potent ligands for HDAC2. 
MATERIALS AND METHODS
 The crystal structure of human HDAC2 
obtained from the protein data bank (PDB) with PDB 
id of 3 MAX20 was used as the reference structure. 
Ligands (185) and decoys (10,300) for HDAC2 from 
DUD-e14 were employed as the test compounds to 
perform retrospective SBVS. All calculations and 
computational simulations were performed on a 
Linux (Ubuntu 12.04 LTS Precise Pangolin) machine 
with Intel® Core™ i5-4210U (1.7 GHz, 3M Cache) 
as the processors and 4 GB of RAM. Computational 
medicinal chemistry applications employed in this 
research were SPORES21, PLANTS1.215,16, BKChem 
(http://bkchem.zirael.org/), Open Babel 2.2.322, 
PyPLIF 0.1.110,11, and PyMOL 1.2r123. Statistical 
analysis was performed by using R 3.1.224.
 The computational methods employed in 
this research mainly referred to previously published 
construction and retrospective validation of an SBVS 
protocol to identify potent ligands for adrenergic b2 
receptor (ADRB2) by Istyastono and Setyaningsih13. 
The crystal structure of human HDAC2 with the 
PDB id of 3MAX20 was downloaded from the PDB 
website (http://www.rcsb.org/pdb/explore/explore.
do?structureId=3max). Only chain A of the crystal 
Fig. 1: Structure of curcuminoids: curcumin (a), 
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structure was used further. The module splitpdb in 
SPORES was employed to split the receptor, the co-
crystal ligand, and the water molecules discovered in 
the pdb file and to subsequently convert the files into 
mol2 files ready to be employed in molecular docking 
simulation employing PLANTS1.2 docking software. 
This procedure produced the virtual target protein.
mol2 and the co-crystal ligand ligand_LLX400_0.
mol2.
 Known HDAC2 active ligands and their 
decoys were downloaded in their SMILES format 
from DUD-e14. There were 185 ligands and 10,300 
decoys downloaded and stored locally as actives_
final.ism and decoys_final.ism. Each compound in 
the file was then subjected to Open Babel 2.2.3 
conversion software to be converted in its three 
dimensional (3D) format at pH 7.4 as a mol2 file. 
The settypes module in SPORES was subsequently 
employed to properly check and assign the mol2 
file into a proper mol2 file ready to dock by using 
PLANTS1.2 docking software.  
 The methods were previously published in 
Istyastono and Setyaningsih13. All virtual screenings 
were performed by molecular docking program 
PLANTS1.2. These steps resulted in ChemPLP 
scores from PLANTS1.2 and Tc-PLIF values from 
PyPLIF for all docking poses.The docking pose with 
the best ChemPLP score or the best Tc-PLIF value 
was selected for each virtually screened compound. 
Virtual screening accuracies were determined in 
terms of the enrichment in True Positives rate (TP) 
reported at a false positive rate (FP) of 1% (EF1%) 
value. The EF1% values were calculated as follows: 
EF1% = ((%TP)/FP1%). 
 Systematic filtering was performed on 
resulted PLIFs. For every filtering result, a new rank 
based on the ChemPLP scores was created and 
the EF1% values were then calculated12,25,26. Only 
poses that have the interaction with the best EF1% 
value were selected for further cutoffs optimization. 
Cutoffs optimization was performed by gradually 
decreasing the ChemPLP score and increasing 
the Tc-PLIF value as the cutoffs. The cutoffs with 
the highest Matthews correlation coefficient (MCC) 
value with the enrichment factor value (EF = (%TP)/
(%FP)) higher than or similar to the EF1%of the best 
bitstring filtered poses were selected for further 
SBVS campaigns. 
 Structures of curcumin, demethoxy 
curcumin,and bis-demethoxy curcumin (Figure 1) 
in two-dimension (2D) in mol file format were built in 
BKChem software and subsequently transformed to 
its SMILES format using Open Babel 2.2.3. Similar 
with the ligand preparation for the retrospective 
validation, each compound was then subjected 
to Open Babel 2.2.3 conversion software to be 
converted in its three dimensional (3D) format at 
pH 7.4 as a mol2 file and the settypes module in 
SPORES was subsequently employed to properly 
check and assign the mol2 file into a proper mol2 file 
ready to dock by using PLANTS1.2 docking software. 
The docking poses were then filtered based on the 
selected bitstring and cutoffs. Compounds with at 
least one pose that met the filtering requirements 
were considered as potent HDAC2 ligands. Visual 
inspections using PyMOL 1.2r123 on the poses 
were performed to investigate manually some 
representative docking poses to obtain insightson 
the HDAC2-ligands binding.
 RESULTS AND DISCUSSION
 Construction and retrospective validation 
of the SBVS protocol to identify potent HDAC2 
ligands
Table 1: The predictive quality of the developed SBVS protocol
SBVS protocol  EF1% when the objective functions used for ranking is
                    ChemPLP Tc-PLIF
Default 15.14 1.08
With filtering on bitstring #117 24.31a) 19.46
aThis value outperforms the EF value of the reference protocol (20.00) (Mysinger et al., 2012).
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 This approach aimed to develop an in silico 
tool to identify potent ligands for HDAC2. Potent 
ligand in this article means ligand with IC50, Ki or 
EC50 equal or less than 1 µM14. The developed SBVS 
protocol should have better EF value compared to 
the reference protocol14, which showed EF value 
of 20.0. The molecular docking simulations on 185 
potent ligands and 10,300 decoys resulted in 31,455 
docking poses which were subsequently subjected 
to PLIF identification and the Tc-PLIF values were 
calculated by comparing the PLIF to the interaction of 
co-crystal ligand N-(4-aminobiphenyl-3-yl)benzamide 
(ligand_LLX400_0.mol2) to HDAC2 (protein.mol2). 
Thence, each pose had two objective functions: 
ChemPLP score and Tc-PLIF value. 
 The default SBVS protocol resulted in EF1% 
values of 15.14 and 1.08 for data series ranked by 
ChemPLP score and Tc-PLIF, respectively. Based on 
the objective functions, one best pose was selected 
for every docked ligand and ranked, resulted in 2 
data series: ChemPLP-ranked and Tc-PLIF-ranked 
datasets. Since the EF1% values were not better than 
the EF value of the reference protocol14, systematic 
filtering on PLIF which was previously reported by 
Istyastono and Setyaningsih13 to identify the most 
important interaction that significantly increased the 
SBVS quality was performed. The results showed that 
filtering on the interaction to bitstring #117 increased 
the EF1% from 15.14 to 24.31 for the ChemPLP-
ranked dataset. On the other hand, the filtering on 
the interaction to bitstring #117 increased the EF1% 
from 1.08 to 19.46 for the Tc-PLIF-ranked dataset. 
This indicated that the hydrogen bond interaction to 
the carbonyl backbone of ALA141 as the hydrogen 
bond acceptor is an important interaction to identify 
potent ligands for HDAC2. Notably, the EF1% value 
after filtering on the interaction outperformed the EF 
value of the reference protocol. These results are 
summarized in Table 1. Nevertheless, very recently 
Istyastono et al.12 has suggested optimizing the 
quality of SBVS by making use of both objective 
functions ChemPLP and Tc-PLIF as the cutoffs.
 The cutoffs optimization discovered that by 
using ChemPLP score of -90.0 as the highest score 
and Tc-PLIF value of 0.50 as the lowest resulted in 
EF value of 30.19. The ChemPLP scores used in the 
optimization were -80.0 to -110.0, while the Tc-PLIF 
used in the optimization were 0.50 to 0.80. Based on 
the EF values, combined cutoffs were divided in to 
cutoffs resulted in EF value of more than or equal to 
24.31 and cutoffs resulted in EF value < 24.31 (Table 
1 and Figure 2A). Subsequently, the cutoffs with the 
best MCC value among cutoffs resulted in EF value 
of more than or equal to 24.31 were selected as the 
optimized cutoffs, i.e. ChemPLP score of -90.0 as the 
highest score and Tc-PLIF value of 0.50 as the lowest 
(Figures 2B and 2C). Based on the results of the 
retrospective validation, the SBVS protocol to identify 
potent HDAC2 developed in this research (Figure 3)
was confidently employed to examine if curcumin, 
Fig. 2: (A) The heat map of EF values on different cutoffs. EF values of equal or more than 24.31 
are represented in red, while EF values of less than 24.31 are represented in blue; (B) The heat 
map and (C) the 3D plot of MCC values on different cutoffs. The MCC values are indicated by the 
colors corresponding to the heat colors on the right side of the map or the 3D plot. As can be 
seen in these figures, using ChemPLP score of -90.0 as the highest score and Tc-PLIF value of 
0.50 as the lowest resulted in EF value of higher than 24.31 and the best MCC value (0.282). 
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Fig. 3: The retrospectively validated SBVS 
protocol to identify potent HDAC2
demethoxy curcumin and bis-demethoxy curcumin 
are potent ligands for HDAC2. Notably, the Tc-PLIF 
value is a reference dependent scoring function10,11, 
which could make the protocol too rigid with less 
predictive ability27. Employing the PLIF bitsrings as 
non-reference dependent predictors could lead to a 
better scoring function.
Curcumin, demethoxy curcumin and bis-
demethoxy curcumin as potent ligands for 
HDAC2
 By employing the SBVS protocol developed 
previously (Figure 3), curcumin, demethoxy 
curcumin and bis-demethoxy curcumin (Figure 1) 
were tested. The results showed that all of them 
were potent ligands for HDAC2 with the number of 
selected poses were 6, 19, and 38 for curcumin, 
demethoxy curcumin and bis-demethoxy curcumin, 
respectively. All selected poses are presented 
in Figure 4, while the representative poses were 
presented in Figure 5. These results are in line with 
the results from Barnes3 and Meja et al.6. Moreover, 
these results suggest that the curcuminoids-rich 
extract of Curcuma longa8,9 could be developed or 
investigated further as potent HDAC2 ligands.
 The potential of curcumin, demethoxy 
curcumin and bis-demethoxy curcumin as inhibitor 
for HDAC2 identified in this research enable them 
to be anticancer agents and to treat Alzheimer’s 
disease due to the overexpression of HDAC2 in 
solid tumors including colon cancer, lung cancer, 
cervical carcinoma, breast cancer, and kidney/
cervix cancer and also in Alzheimer’s disease28,29.
As HDAC inhibitors, these curcuminoids may alter 
phosphorylation30 and/ or reduce the stability of tau 
protein31,32, resulting in decreased clinical features of 
tauopathies, a class of neurodegenerative diseases 
associated with the pathological aggregation of 
tau protein in the human brain. The best known of 
these illnesses is Alzheimer’s disease, wherein tau 
protein is deposited within neurons in the form of 
neurofibrillary tangles.These curcuminoids as HDAC 
inhibitors couldal so suppress cancer by inducing the 
G1/S phase arrest primarily through transcriptional 
changes in cell cycle regulatory genes33.
CONCLUSIONS
 A retrospective validation on an SBVS 
protocol to identify potent HDAC2 ligands employing 
molecular docking using PLANTS1.2 and PLIF 
identification using PyPLIF resulted in EF value 
of 30.19. The protocol employed filtering on the 
hydrogen bond interaction to the carbonyl backbone 
of ALA141of HDAC2 and selecting only poses with 
ChemPLP score is similar or lower than -90.0 and Tc-
PLIF value is similar or higher than 0.50 (Figure 3). 
The protocol was then employed to screen curcumin, 
demethoxy curcumin and bis-demethoxy curcumin 
and the results showed that all of them were potent 
ligands for HDAC2. The selected docking poses of 
curcumin, demethoxy curcumin and bis-demethoxy 
curcumin (Figures 4 and 5) could be used as 
insights in further design and discovery novel HDAC2 
ligands.  
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Fig. 4: All selected poses as potent HDAC2 ligands of (A) curcumin (carbons are colored in 
yellow), (B) demethoxy curcumin (carbons are colored in orange) and (C) bis-demethoxy 
curcumin(carbons are colored in cyan) in the HDAC2 binding pocket. The co-crystal ligand N- 
(4-aminobiphenyl-3-yl) benzamide (carbons are colored in magenta) and the zinc ion (grey) are 
presented in all figures. For the sake of clarity, only the backbone atoms of the HDAC2 protein 
(carbons are colored in green) are presented, while hydrogen is not shown. The protein is 
presented in the cartoon mode, the co-crystal ligand in the stick mode, the zinc ion in the sphere 
mode, while curcumin, demethoxy curcumin and bis-demethoxy curcumin are presented in line 
mode. Oxygen and nitrogen are colored in red and blue, respectively. These figures are prepared 
using PyMOL 1.2r123
Fig. 5: Representative poses of (A) curcumin (carbons are colored in yellow), (B) demethoxy 
curcumin (carbons are colored in orange) and (C) bis-demethoxy curcumin (carbons are 
colored in cyan) in the HDAC2 binding pocket. For the sake of clarity, only the backbone atoms 
and residue ALA141 of the HDAC2 protein (carbons are colored in green) are presented, while 
hydrogen is not shown. The protein is presented in the cartoon mode, the zinc ion (grey) in the 
sphere mode, while curcumin, demethoxy curcumin and bis-demethoxy curcumin are presented 
in stick mode. Hydrogen, oxygen and nitrogen are colored in white, red and blue, respectively. 
Hydrogen bonds and ion-dipole interactions are represented in black and magenta dashed lines, 
respectively. These figures are prepared using PyMOL 1.2r123
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